Eli Lilly and Company (LLY)
Eli Lilly (LLY) Q1 Earnings Lag Estimates
Eli Lilly (LLY) came out with quarterly earnings of $3.34 per share, missing the Zacks Consensus Estimate of $3.52 per share. This compares to earnings of $2.58 per share a year ago.
Eli Lilly Revenue Up on Demand for Mounjaro, Other Weight-Loss Meds
Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.
Eli Lilly Stock Slips as Lowered Profit Outlook Outweighs Solid Q1 Results
Shares of Eli Lilly (LLY) fell in premarket trading Thursday after the pharmaceutical giant's lowered profit projections outweighed first-quarter results that came in above analysts' expectations.
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
Eli Lilly topped first-quarter earnings and revenue estimates. The drugmaker said sales of weight loss drug Zepbound and diabetes treatment Mounjaro spiked in the first quarter.
Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More
Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (LLY 1.09%). It is the most valuable healthcare company in the world, with a market cap of around $800 billion.
Eli Lilly: Why Orforglipron Matters, A Lot
Eli Lilly and Company's orforglipron generated positive results in the phase 3 trial in type 2 diabetes patients. The results look good or better than oral semaglutide (across trials) and similar to injectable semaglutide. The importance of these LLY results cannot be understated, as this should be the first oral obesity product that can be produced at scale to satisfy global demand.
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Eli Lilly Stock Moves Lower on Rare Double Downgrade
Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to "reduce" from "buy," and a price-target cut to $700 from $1,150.
Ahead of Lilly (LLY) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
How Eli Lilly and Novo Nordisk have separated themselves from their rivals
Most companies are likely going to feel the impact of President Trump's tariffs. In the video above, BofA Securities senior pharma & biotech analyst Tim Anderson describes how tariffs will impact the pharmaceutical stocks he covers.
Eli Lilly Will Be the Next $1 Trillion Stock
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so.
